Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2025) 110 EP1470 | DOI: 10.1530/endoabs.110.EP1470

ECEESPE2025 ePoster Presentations Thyroid (198 abstracts)

Effectiveness of antithyroid therapy on TH1, TH17, and TH22 lymphocytes in pediatric Graves’ patients

Artur Bossowski 1 , Aleksandra Starosz 2 , Karolina Stozek 1 , Filip Bossowski 3 , Marcin Moniuszko 1 2 & Kamil Grubczak 1 2


1Medical University in Bialystok, Department of Pediatric Endocrinology and Diabetes with a Cardiology Unit, Bialystok, Poland; 2Medical University in Bialystok, Department of Medical Immunology, Faculty of Medicine, Bialystok, Poland; 3Medical University in Bialystok, Department of Paediatrics, Endocrinology and Diabetes with a Cardiology Divisions, Bialystok, Poland.


JOINT2491

Graves’ disease is the leading cause of autoimmune hyperthyroidism. Thyroid hormones are an essential element of the endocrine system, playing a pivotal role in the body’s development, especially important in children with intensified growth. Disturbance within thyroid tissue certainly affected the whole body. Nowadays, numerous research studies indicate different factors contributing to the onset of the disease; however, the exact pathomechanism of Graves’ disease is still not fully understood, especially in the context of immune-related processes. Th1, Th17, and Th22 effector lymphocytes were found to be crucial participants in the disease outcome, as well as in autoimmune diseases. Here, our study aimed at assessing selected effector T lymphocytes, Th1, Th17, and Th22, in newly diagnosed pediatric Graves’ disease patients, together with their association with thyroid-related parameters and the potential outcome of disease management. We indicated significant increases in the frequencies and absolute numbers of selected effector lymphocytes in Graves’ disease patients. In addition, their mutual ratios, as well as Th1/Th17, Th/Th22, and Th17/Th22, seem to be significant in those diseases. Notably, low Th17/Th22 ratio values were distinguished as potential prognostic factors for normalizing TSH levels in response to methimazole treatment. To sum up, our research determines the crucial contribution of Th1, Th17, and Th22 cells in the pathogenesis of Graves’ disease. Moreover, the mentioned subset of T cells is highly likely to play a substantial role in the potential prediction of therapy outcomes.

Volume 110

Joint Congress of the European Society for Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE) 2025: Connecting Endocrinology Across the Life Course

European Society of Endocrinology 
European Society for Paediatric Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches